Loading…
Anavex Life Sciences Corp. is projected to rise to $2.86 by 2027, a +4% move from its current price of $2.76. AVXL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.68 | $2.76 | $2.85 | +0.01% |
| May 30 | $2.64 | $2.76 | $2.88 | +0.02% |
| May 31 | $2.62 | $2.76 | $2.91 | +0.03% |
| Jun 1 | $2.60 | $2.76 | $2.94 | +0.04% |
| Jun 2 | $2.58 | $2.76 | $2.96 | +0.05% |
| Jun 3 | $2.56 | $2.76 | $2.98 | +0.06% |
| Jun 4 | $2.55 | $2.76 | $3.00 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.55 | $2.76 | $3.00 | +0.07% |
| Week 2 | $2.46 | $2.76 | $3.10 | +0.14% |
| Week 3 | $2.40 | $2.77 | $3.18 | +0.21% |
| Week 4 | $2.35 | $2.77 | $3.26 | +0.29% |
| Week 5 | $2.31 | $2.77 | $3.32 | +0.36% |
| Week 6 | $2.27 | $2.77 | $3.38 | +0.43% |
| Week 7 | $2.24 | $2.77 | $3.44 | +0.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anavex Life Sciences Corp. operates as a biopharmaceutical company focused on developing CNS-acting therapies. It pursues treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental and neurodegenerative disorders, Rett syndrome, other CNS conditions, pain, and various cancers, according to its description of activities and scope.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has progressed through Phase 2a and Phase 2b/3 trials for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and a Phase 2/3 study in Rett syndrome among pediatric patients. ANAVEX 3-71 is another clinical stage candidate targeting SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity in Alzheimer's disease models in mice. These details establish Anavex Life Sciences as a research-focused biopharmaceutical company with multiple CNS-focused programs and a pipeline that includes SIGMAR1-targeting therapies.
AVXL is the stock ticker for Anavex Life Sciences Corp. The current price is $2.70 and the market cap is $249.75M, with a rank of 3666. The current price sits within a forecast-informed outlook that envisions a gradual multi-year appreciation, with 2026 forecasted at an avg of $2.70 and later years showing higher potential.
The long-horizon view projects a rising trajectory, culminating in a 2050 avg of $15.01 and a max of $29.70, illustrating a broad range of potential outcomes.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.3% below — buyers have tended to step in here.
The nearest ceiling, 32.2% above — a clean break opens room to run.
A major ceiling 92.0% above — clearing it would confirm fresh momentum.
Key AVXL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVXL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.73 | Buy | $2.75 | Buy |
| MA 10 | $2.82 | Sell | $2.83 | Sell |
| MA 20 | $3.05 | Sell | $2.98 | Sell |
| MA 50 | $3.25 | Sell | $3.32 | Sell |
| MA 100 | $3.87 | Sell | $3.94 | Sell |
| MA 200 | $5.58 | Sell | $5.09 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.10 | Neutral |
| Stoch RSI (14) | 41.12 | Neutral |
| CCI (20) | -83.52 | Neutral |
| Williams %R (14) | -84.21 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -14.29 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 15.79 | Buy |
| TRIX (15) | -0.66 | Sell |
| Awesome (5,34) | -0.44 | Sell |
| Ultimate (7,14,28) | 31.22 | Neutral |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 2.68 | Buy |
| ADX (14) | 22.40 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bearish. RSI14 is 30, and the stock trades in a 30-day range from $2.18 to $3.34. The short-term moving averages sit at SMA50 of $3.33 and SMA200 of $5.67, indicating weaker near-term momentum relative to the longer trend. Nearby support is at $2.67 and resistance at $3.65, suggesting a potential trading band in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.67 | $2.76 | $3.69 | 0% | Neutral | |
| $2.24 | $2.86 | $3.88 | +4% | Neutral | |
| $2.22 | $2.92 | $4.12 | +6% | Neutral | |
| $2.36 | $3.18 | $4.63 | +15% | Neutral | |
| $2.38 | $3.28 | $4.91 | +19% | Neutral | |
| $2.98 | $4.21 | $6.45 | +53% | Bullish | |
| $3.31 | $4.77 | $7.45 | +73% | Bullish | |
| $3.01 | $4.42 | $7.04 | +60% | Bullish | |
| $3.10 | $4.63 | $7.50 | +68% | Bullish | |
| $3.18 | $4.84 | $7.95 | +75% | Bullish | |
| $4.38 | $7.20 | $12.65 | +161% | Bullish | |
| $8.00 | $15.06 | $29.15 | +446% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.67 | $2.76 | $3.25 | +0.00% |
| June 2026 | $2.34 | $2.76 | $3.33 | +0.00% |
| July 2026 | $2.34 | $2.79 | $3.41 | +0.93% |
| August 2026 | $2.41 | $2.89 | $3.58 | +3.66% |
| September 2026 | $2.39 | $2.88 | $3.60 | -0.34% |
| October 2026 | $2.30 | $2.79 | $3.52 | -3.11% |
| November 2026 | $2.31 | $2.82 | $3.58 | +0.97% |
| December 2026 | $2.35 | $2.88 | $3.69 | +2.29% |
Click any year to see its month-by-month AVXL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVXL to range from $2.67 to $3.69 through 2026. The $2.76 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AVXL price prediction for 2027 points to an average of $2.86 (low $2.24, high $3.88) — a potential gain of +4% on today's $2.76. A consolidation phase looks the most probable path here.
In 2028, AVXL is projected to trade between $2.22 and $4.12, averaging $2.92 — a potential gain of +6% from today's $2.76. That is up +2% on the projected 2027 average. Price action looks broadly range-bound.
Anavex Life Sciences Corp.'s 2029 outlook centres on $3.18, within a $2.36 to $4.63 range. That is up +9% on the projected 2028 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, AVXL could reach as high as $4.91, with a base case around $3.28 and support toward $2.38 — roughly +19% from $2.76. Price action looks broadly range-bound.
Expect AVXL to range from $2.98 to $6.45 through 2031. The $4.21 average target implies a +53% move from current prices. That is up +28% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AVXL price prediction for 2032 points to an average of $4.77 (low $3.31, high $7.45) — a potential gain of +73% on today's $2.76. Momentum favours further upside here.
In 2033, AVXL is projected to trade between $3.01 and $7.04, averaging $4.42 — a potential gain of +60% from today's $2.76. That is -7% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Anavex Life Sciences Corp.'s 2034 outlook centres on $4.63, within a $3.10 to $7.50 range. That is up +5% on the projected 2033 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2035, AVXL could reach as high as $7.95, with a base case around $4.84 and support toward $3.18 — roughly +75% from $2.76. Buyers look set to stay in control over this stretch.
Expect AVXL to range from $4.38 to $12.65 through 2040. The $7.20 average target implies a +161% move from current prices. That is up +49% on the projected 2035 average. Momentum favours further upside here.
The AVXL price prediction for 2050 points to an average of $15.06 (low $8.00, high $29.15) — a potential gain of +446% on today's $2.76. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVXL today (≈ 362.318841 AVXL) could be worth
$5,457.75
+$4,457.75 (+446%) by 2050 · US Dollar
Based on the average projected AVXL price of $15.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVXLwould be worth at today's price.
$1,000 invested in AVXL on May 27, 2025 (≈ 135.685212 AVXL) would be worth
$374.49
-$625.51 (-62.6%) today · 0.37× · US Dollar
Based on a AVXL entry price of $7.37 vs. today's $2.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.75 | $1,003.64 | +0.4% |
| 1 month ago | $3.29 | $838.91 | -16.1% |
| 3 months ago | $4.46 | $618.83 | -38.1% |
| 6 months ago | $3.83 | $720.63 | -27.9% |
| 1 year ago | $7.37 | $374.49 | -62.6% |
| All time (5.0y) ago | $12.49 | $220.98 | -77.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVXL forecast.
Our base-case forecast reaches $5.50 around 2040.
Implied market cap at $5.50: $509.69M
The multi-year forecast shows a path of gradual to significant upside in the years ahead. For 2026 the avg is $2.70 with a min of $2.67 and a max of $3.63 and ROI 0, reflecting a flat near-term stance. By 2030 the avg rises to $3.21 with ROI 18.9 and a neutral sentiment, signaling modest appreciation into the decade.
In 2031 the avg climbs to $4.19 with ROI 55.5 and becomes bullish; by 2032 the avg is $4.72 (ROI 75) and by 2033 it is $4.32 (ROI 60.1). The forecast continues bullish into 2040, with an avg of $7.16 and ROI 165.9; and by 2050 the avg is $15.01 with ROI 457.1, highlighting substantial long-term upside potential. These figures imply a rising trajectory through the 2030s and beyond, but as with all forecasts they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $3.21 with a min of $2.29 and a max of $4.85, and ROI 18.9, with a neutral sentiment.
Longer-term forecasts show a bullish stance starting in 2031, with 2031 avg $4.19 (ROI 55.5) and 2040 avg $7.16 (ROI 165.9), culminating in 2050 avg $15.01 (ROI 457.1). These are estimates and not guarantees.
Yes, the forecast shows potential upside beyond $10, with 2040 max $12.83 and 2050 max $29.70, indicating it could exceed $10 in the 2040s or by 2050.
The current price is $2.70 and the market cap is $249.75M.
For 2026 the min is $2.67, avg $2.70, max $3.63, with sentiment Neutral.
Anavex Life Sciences Corp. Community Discussion
0Share your Anavex Life Sciences Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.